Abstract 609P
Background
Pembrolizumab, a checkpoint inhibitor, has revolutionized the treatment of advanced melanoma by harnessing the immune system to target cancer cells. However, its use is associated with immune-related adverse events, including vitiligo and thyroid function abnormalities. This study aims to investigate the association between thyroid function abnormalities and vitiligo induced by pembrolizumab, specifically focusing on the prognosis in patients with advanced melanoma.
Methods
A retrospective survey of medical records and treatment outcomes of patients with locally advanced/metastatic melanoma receiving pembrolizumab was conducted. The study reported data on the incidence of vitiligo, thyroid function abnormalities, and their impact on prognosis. Data was collected from multiple oncology centers across Iraq. Kaplan-Meier survival curves and Cox regression were used for statistical analysis.
Results
One hundred cases with advanced melanoma were included in this study. The mean age of the samples was 55.8 ± 15.5 years old. Male to female ratio was 0.79. The Incidence of vitiligo was reported to be 27%, mainly in the survived-group (35.2%, P-value = 0.046). It took an average of 12 weeks for the development of vitiligo. The incidence of thyroid dysfunction was found to be 22%. The development of vitiligo significantly improved survival in patients with advanced melanoma (log-rank test = 0.043). On the other hand, the occurrence of thyroid dysfunction as an immune-side effect to treatment did not have an effect on the overall survival of the cohort.
Conclusions
The findings of this study suggest that there is an association between the incidence of vitiligo induced by pembrolizumab and overall survival in patients with advanced melanoma. However, no such relationship was found in regard to the development of thyroid dysfunction.
Clinical trial identification
Editorial acknowledgement
Dr. Ahmed Z. Al-Samaraee, Medical oncologist, Oncology teaching hospital, Baghdad Dr Maha S. Sahib, Clinical Pharmacist, Baghdad Dr Ayad R Alasadi, Medical oncologist, Al-Amal Hospital, Baghdad.
Legal entity responsible for the study
Oncology Teaching Hospital, Medical City Complex, Baghdad.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract